# GSK

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/gsk
Canonical HTML page: https://getfinancebrief.com/entity/gsk

## Recent coverage (3 stories)

### GSK Stock Jumps on 15% Q1 Sales Rise
2026-04-30 04:50:42 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

GSK's Q1 sales growth of 15% and reaffirmed guidance could sway market indices, drawing investor attention to healthcare stocks. This performance highlights potential for dividend yields and stock valuation shifts in volatile markets. Finance experts should analyze the broader economic impacts on pharmaceutical investments.
Full story: https://getfinancebrief.com/story/gsk-q1-earnings-finance-analysis

### Pharma Earnings: Wave Life Sciences and Collegium Report 2025 Results
2026-02-26 14:29:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Full story: https://getfinancebrief.com/story/wave-life-sciences-collegium-2025-earnings-analysis

### FDA Reverses Stance on Moderna’s mRNA Flu Shot, Clearing Path for Review
2026-02-18 21:43:09 · Sentiment: Bullish · Impact: 7/10 · Sources: 3

The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Full story: https://getfinancebrief.com/story/fda-reversal-moderna-mrna-flu-shot-review

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.